Literature DB >> 26884583

Bispecific T-Cell Engagers (BiTEs) as Treatment of B-Cell Lymphoma.

Nicole C Smits1, Charles L Sentman2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26884583      PMCID： PMC5085271          DOI： 10.1200/JCO.2015.64.9970

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  26 in total

1.  Recombination of a mixture of univalent antibody fragments of different specificity.

Authors:  A NISONOFF; M M RIVERS
Journal:  Arch Biochem Biophys       Date:  1961-05       Impact factor: 4.013

Review 2.  Bispecific antibodies.

Authors:  Roland E Kontermann; Ulrich Brinkmann
Journal:  Drug Discov Today       Date:  2015-02-26       Impact factor: 7.851

Review 3.  The therapeutic monoclonal antibody market.

Authors:  Dawn M Ecker; Susan Dana Jones; Howard L Levine
Journal:  MAbs       Date:  2015       Impact factor: 5.857

4.  Blinatumomab approved for rare leukemia.

Authors:  Kate Traynor
Journal:  Am J Health Syst Pharm       Date:  2015-01-15       Impact factor: 2.637

5.  A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma.

Authors:  Achim Rothe; Stephanie Sasse; Max S Topp; Dennis A Eichenauer; Horst Hummel; Katrin S Reiners; Markus Dietlein; Georg Kuhnert; Joerg Kessler; Carolin Buerkle; Miroslav Ravic; Stefan Knackmuss; Jens-Peter Marschner; Elke Pogge von Strandmann; Peter Borchmann; Andreas Engert
Journal:  Blood       Date:  2015-04-17       Impact factor: 22.113

6.  Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.

Authors:  Max S Topp; Peter Kufer; Nicola Gökbuget; Mariele Goebeler; Matthias Klinger; Svenja Neumann; Heinz-A Horst; Thorsten Raff; Andreas Viardot; Mathias Schmid; Matthias Stelljes; Markus Schaich; Evelyn Degenhard; Rudolf Köhne-Volland; Monika Brüggemann; Oliver Ottmann; Heike Pfeifer; Thomas Burmeister; Dirk Nagorsen; Margit Schmidt; Ralf Lutterbuese; Carsten Reinhardt; Patrick A Baeuerle; Michael Kneba; Hermann Einsele; Gert Riethmüller; Dieter Hoelzer; Gerhard Zugmaier; Ralf C Bargou
Journal:  J Clin Oncol       Date:  2011-05-16       Impact factor: 44.544

Review 7.  Monoclonal antibody-based therapies in the treatment of acute lymphoblastic leukemia.

Authors:  Mark R Litzow
Journal:  Am Soc Clin Oncol Educ Book       Date:  2013

8.  Bispecific and trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine production.

Authors:  Michelle K Gleason; Michael R Verneris; Deborah A Todhunter; Bin Zhang; Valarie McCullar; Sophia X Zhou; Angela Panoskaltsis-Mortari; Louis M Weiner; Daniel A Vallera; Jeffrey S Miller
Journal:  Mol Cancer Ther       Date:  2012-10-17       Impact factor: 6.261

9.  Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy.

Authors:  David T Teachey; Susan R Rheingold; Shannon L Maude; Gerhard Zugmaier; David M Barrett; Alix E Seif; Kim E Nichols; Erica K Suppa; Michael Kalos; Robert A Berg; Julie C Fitzgerald; Richard Aplenc; Lia Gore; Stephan A Grupp
Journal:  Blood       Date:  2013-05-15       Impact factor: 22.113

10.  Long-term follow-up of serum immunoglobulin levels in blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemia.

Authors:  G Zugmaier; M S Topp; S Alekar; A Viardot; H-A Horst; S Neumann; M Stelljes; R C Bargou; M Goebeler; D Wessiepe; E Degenhard; N Gökbuget; M Klinger
Journal:  Blood Cancer J       Date:  2014-09-05       Impact factor: 11.037
View more
  17 in total

Review 1.  Novel Treatments for Mantle Cell Lymphoma: From Targeted Therapies to CAR T Cells.

Authors:  Danielle Wallace; Patrick M Reagan
Journal:  Drugs       Date:  2021-03-30       Impact factor: 9.546

2.  Tailoring CD19xCD3-DART exposure enhances T-cells to eradication of B-cell neoplasms.

Authors:  Paola Circosta; Angela Rita Elia; Indira Landra; Rodolfo Machiorlatti; Maria Todaro; Sabrina Aliberti; Davide Brusa; Silvia Deaglio; Sabina Chiaretti; Riccardo Bruna; Daniela Gottardi; Massimo Massaia; Filomena Di Giacomo; Anna Rita Guarini; Robin Foà; Peter W Kyriakides; Rohan Bareja; Olivier Elemento; Gurunadh R Chichili; Emanuele Monteleone; Paul A Moore; Syd Johnson; Ezio Bonvini; Alessandro Cignetti; Giorgio Inghirami
Journal:  Oncoimmunology       Date:  2018-02-08       Impact factor: 8.110

Review 3.  Bispecific antibodies in cancer immunotherapy.

Authors:  Eva Dahlén; Niina Veitonmäki; Per Norlén
Journal:  Ther Adv Vaccines Immunother       Date:  2018-03-28

Review 4.  Advancing Cancer Therapy with Present and Emerging Immuno-Oncology Approaches.

Authors:  Jeff Kamta; Maher Chaar; Anusha Ande; Deborah A Altomare; Sihem Ait-Oudhia
Journal:  Front Oncol       Date:  2017-04-18       Impact factor: 6.244

Review 5.  A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies.

Authors:  Kensei Tobinai; Christian Klein; Naoko Oya; Günter Fingerle-Rowson
Journal:  Adv Ther       Date:  2016-12-21       Impact factor: 3.845

Review 6.  Bispecific, T-Cell-Recruiting Antibodies in B-Cell Malignancies.

Authors:  Margaux Lejeune; Murat Cem Köse; Elodie Duray; Hermann Einsele; Yves Beguin; Jo Caers
Journal:  Front Immunol       Date:  2020-05-07       Impact factor: 7.561

7.  Therapeutic Bispecific T-Cell Engager Antibody Targeting the Transferrin Receptor.

Authors:  Mingpeng Fu; Qi He; Zilong Guo; Xiaoran Zhou; Heli Li; Liang Zhao; Hongling Tang; Xiaoqi Zhou; Huifen Zhu; Guanxin Shen; Yong He; Ping Lei
Journal:  Front Immunol       Date:  2019-06-21       Impact factor: 7.561

Review 8.  Insights Into Lung Cancer Immune-Based Biology, Prevention, and Treatment.

Authors:  Sara Saab; Hussein Zalzale; Zahraa Rahal; Yara Khalifeh; Ansam Sinjab; Humam Kadara
Journal:  Front Immunol       Date:  2020-02-11       Impact factor: 7.561

9.  JAK/STAT-Dependent Chimeric Antigen Receptor (CAR) Expression: A Design Benefiting From a Dual AND/OR Gate Aiming to Increase Specificity, Reduce Tumor Escape and Affect Tumor Microenvironment.

Authors:  Javad Khanali; Mohammadreza Azangou-Khyavy; Melika Boroomand-Saboor; Mobina Ghasemi; Hassan Niknejad
Journal:  Front Immunol       Date:  2021-06-09       Impact factor: 7.561

Review 10.  Combining Oncolytic Viruses With Cancer Immunotherapy: Establishing a New Generation of Cancer Treatment.

Authors:  Tao Shi; Xueru Song; Yue Wang; Fangcen Liu; Jia Wei
Journal:  Front Immunol       Date:  2020-04-28       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.